EpiPen price increases :  how regulatory barriers inhibit pharmaceutical competition : field hearing of the Subcommittee on Children and Families of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session on examining EpiPen price increases, focusing on how regulatory barriers inhibit pharmaceutical competition, October 7, 2016 (Lexington, KY). 
 How regulatory barriers inhibit pharmaceutical competition 

 - 1 online resource (iii, 43 pages) :  illustrations. 
 - S. hrg. ;  114-805 .
 - United States.  Congress.  Senate.  S. hrg. ;  114-805. .
<br/><br/> CRDP Program record. 
<br/><br/>Includes bibliographical references. 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Prescription pricing--United States.<br/>Drugs--Law and legislation--United States.<br/>Pharmaceutical industry--United States.<br/>Competition--United States.<br/>Drug delivery devices--Prices--United States.
<br/><br/><label>Index Terms--Genre/Form: </label><br/>Legislative hearings.
<br/><br/><label>LC Class. No.: </label>KF26  / .L2733 2016 
<br/><br/><label>GPO Item No.: </label>1043-C (online) 
<br/><br/><label>Gov. Doc. Class. No.: </label>Y 4.L 11/4:S.HRG.114-805